ZLAB - Zai Lab Limited
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors.
As of Oct 14, 2026: spot at $22.50, ATM IV 72.5%, max pain $25.00, net GEX -$144.5K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $2.61B
- Beta
- 0.83
- 52-Week Range
- 15.96-30.18
- CEO
- Ying Du
- Employees
- 1,784
- IPO Date
- Sep 20, 2017
- Exchange
- NASDAQ
What ZLAB Looks Like to Options Traders Today
IV rank of 11.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); negative net gamma exposure (-$144.5K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (-0.045) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The ZLAB overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ZLAB overview questions
- What is ZLAB?
- ZLAB is the ticker symbol for Zai Lab Limited, a listed security. Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Listed on NASDAQ. ZLAB is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ZLAB options snapshot look like today?
- As of Oct 14, 2026, the ZLAB options snapshot shows spot at $22.50, ATM IV 72.5%, IV rank 11.1%, max pain $25.00, net GEX -$144.5K, expected move 20.79%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ZLAB's key statistics?
- Zai Lab Limited (ZLAB) carries a market capitalization of $2.61B, beta of 0.83 relative to the broader market, 52-week range of 15.96-30.18. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ZLAB belong to?
- Zai Lab Limited operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ZLAB's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ZLAB data on this page?
- The options snapshot above is dated Oct 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).